WO2005097976A1 - 抗原パルスして得られた樹状細胞 - Google Patents
抗原パルスして得られた樹状細胞 Download PDFInfo
- Publication number
- WO2005097976A1 WO2005097976A1 PCT/JP2005/006679 JP2005006679W WO2005097976A1 WO 2005097976 A1 WO2005097976 A1 WO 2005097976A1 JP 2005006679 W JP2005006679 W JP 2005006679W WO 2005097976 A1 WO2005097976 A1 WO 2005097976A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- cells
- hepatitis
- pulsed
- human
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 304
- 239000000427 antigen Substances 0.000 title claims abstract description 210
- 102000036639 antigens Human genes 0.000 title claims abstract description 210
- 108091007433 antigens Proteins 0.000 title claims abstract description 210
- 229960005486 vaccine Drugs 0.000 claims abstract description 402
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 107
- 201000010099 disease Diseases 0.000 claims abstract description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 64
- 210000004027 cell Anatomy 0.000 claims description 228
- 241000282414 Homo sapiens Species 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 80
- 238000011282 treatment Methods 0.000 claims description 70
- 210000004369 blood Anatomy 0.000 claims description 49
- 239000008280 blood Substances 0.000 claims description 49
- 230000002265 prevention Effects 0.000 claims description 49
- 238000004519 manufacturing process Methods 0.000 claims description 41
- 208000006454 hepatitis Diseases 0.000 claims description 37
- 241000282412 Homo Species 0.000 claims description 34
- 231100000283 hepatitis Toxicity 0.000 claims description 30
- 230000028993 immune response Effects 0.000 claims description 23
- 239000011886 peripheral blood Substances 0.000 claims description 23
- 210000005259 peripheral blood Anatomy 0.000 claims description 23
- 239000000654 additive Substances 0.000 claims description 22
- 241000700721 Hepatitis B virus Species 0.000 claims description 21
- 229960002520 hepatitis vaccine Drugs 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 17
- 230000000996 additive effect Effects 0.000 claims description 17
- 210000000601 blood cell Anatomy 0.000 claims description 17
- 210000001616 monocyte Anatomy 0.000 claims description 15
- 230000003213 activating effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 11
- 229940030156 cell vaccine Drugs 0.000 claims description 11
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 26
- 239000000126 substance Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000005087 mononuclear cell Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 238000011160 research Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000010876 biochemical test Methods 0.000 description 6
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 6
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- -1 HB vaccine Proteins 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 229960001627 lamivudine Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000011076 safety test Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 208000018583 New-onset refractory status epilepticus Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 239000011449 brick Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940124589 immunosuppressive drug Drugs 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 231100000354 acute hepatitis Toxicity 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001147 anti-toxic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000035584 blastogenesis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 229940047091 other immunostimulants in atc Drugs 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 229960002109 tuberculosis vaccine Drugs 0.000 description 2
- 229940021648 varicella vaccine Drugs 0.000 description 2
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000015864 Protobothrops flavoviridis Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- CPYGEBRERVOSHG-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].[Al+3].[Na+].[K+] Chemical compound S(=O)(=O)([O-])[O-].[Al+3].[Na+].[K+] CPYGEBRERVOSHG-UHFFFAOYSA-L 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000028207 Weil disease Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000005208 blood dendritic cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940095293 mumps vaccine Drugs 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 229960003131 rubella vaccine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 229960001515 yellow fever vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- Dendritic cells obtained by antigen pulse obtained by antigen pulse
- the present invention relates to dendritic cells that can be used for preventing or treating diseases.
- dendritic cell therapy which is a type of cell immunotherapy.
- the dendritic cells are antigen pre-senting cells (APCs) that have the strongest antigen-presenting ability in vivo, and activate ⁇ cells by presenting the taken-in antigen epitope to T cells.
- the immune response can be enhanced.
- the dendritic cell therapy is a therapy in which the dendritic cells are pulsed in vitro using a substance extracted from cancer cells or a cancer-specific antigen to enhance the antigen-presenting ability and return the cells to the living body. is there.
- Cancer cell power The extracted substance is generally a mixture of various kinds of substances. Therefore, dendritic cells pulsed with a substance extracted from cancer cells are considered to have been pulsed by various types of cancer antigens in the cell extract, and a strong immune response against cancer was induced. Expected to be. However, when such a mixture of various substances is pulsed, the antigen presented by dendritic cells cannot be identified. Therefore, use for cancer patients is permitted. Use for healthy individuals is not allowed.
- Hepatitis is an inflammation of the liver that is caused primarily by viruses, alcohol, and drugs. The most common hepatitis is due to the hepatitis virus, and to date, seven hepatitis viruses have been found. In Japan, hepatitis B and C dominate.
- Hepatitis can be roughly divided into acute hepatitis and chronic hepatitis, and chronic hepatitis refers to hepatitis that lasts for more than 6 months.
- Hepatitis A is orally transmitted, remains acute hepatitis and does not become chronic.
- Hepatitis B and C are transmitted through the blood, with vertical transmission between mother and child and horizontal transmission between family members and heterosexuals.
- Hepatitis B and C are said to have an extremely high rate of transition to severe liver diseases such as cirrhosis and liver cancer when acute hepatitis often progresses to chronic hepatitis and becomes chronic.
- Hepatitis B patients are distributed worldwide, and there are reportedly 350 million hepatitis B virus-infected people worldwide.
- the number of infected people in China is estimated to be 120 million, and it is estimated that it accounts for more than 70% of the total number of infected people in Southeast Asia. It is reported that about 1 million people die each year worldwide from the disease.
- Japan it is estimated that there are more than one million people infected with hepatitis B virus, of which about 10% are chronic hepatitis patients.
- hepatitis B There is no specific cure for hepatitis B. Thus, treatment is aimed at reducing the number of viruses and their activity. As typical treatment methods, interferon therapy and lamivudine therapy are known.
- Interferon therapy is the first treatment for hepatitis B started about 20 years ago. Interferon helps the immune system to suppress virus growth. Interferon therapy can be expected to be effective as the number of viruses decreases, so it is generally effective in treating hepatitis C, which is one-thousandth of hepatitis ⁇ , while hepatitis B Is only effective in about 20% of patients. Interferon becomes more effective when the liver shifts to cirrhosis. In addition, the interface used for treatment One feron costs a lot of money to develop and produce, and there are many problems, such as one course of treatment that brings a large financial burden of 2 to 3 million yen to patients.
- Lamivudine is a drug originally developed as a remedy for AIDS, but is known to be effective also in the treatment of hepatitis B. Lamivudine has the effect of directly suppressing the synthesis of viral DNA, and has the effect of stopping the rapid deterioration of hepatitis B from illness. Lamivudine has also been reported to be effective in patients with potent hepatitis B where interferon had no effect, but was not effective when the virus was not in a proliferative state. Furthermore, there is a problem that lamivudine-resistant virus appears by long-term administration.
- HB vaccine is generally effective.
- HB vaccines are based on the HBs antigen, the surface antigen of hepatitis B virus. Normally, three doses of this HB vaccine produce anti-HBs antibodies in the body for humans who respond to the HB vaccine. Humans who have developed antibodies will not subsequently be infected with hepatitis B, but even if antibody levels decline several years later, they may be able to escape infection once anti-HBs antibodies are formed in the body it is conceivable that. In addition, antibody levels can be increased again by booster shots.
- the object of the present invention is to provide dendritic cells that are effective for the prevention or treatment of diseases, and in particular, to provide dendritic cells that can be suitably used for the prevention or treatment of hepatitis B.
- the dendritic cells having the ability to present HBs antigen of the present invention are dendritic cells having the ability to present HBs antigen obtained by a method including a step of pulsating dendritic cells with HBs antigen.
- the dendritic cells of the present invention having the ability to present HBs antigen can activate T cells by presenting the HBs antigen epitope to the T cells, and can enhance the immune response to the HBs antigen. Therefore, according to the present invention, it is possible to provide a dendritic cell having an HBs antigen presenting ability, which is effective for preventing or treating hepatitis B.
- the method preferably further includes a step of obtaining the dendritic cells from blood.
- a step of obtaining the dendritic cells from blood it is possible to provide the HBs antigen-presenting DCs of the present invention from DCs derived from blood.
- a relatively simple operation can be performed using a conventionally known method or the like. It is possible to obtain dendritic cells.
- the method preferably further comprises a step of collecting the blood from an organism.
- the organism is preferably a human. According to this, human-derived dendritic cells can be obtained, and thus dendritic cells having the ability to present HBs antigen according to the present invention can be administered to humans. Therefore, according to the present invention, it is possible to provide a dendritic cell capable of presenting HBs antigen, which is effective in preventing or treating hepatitis B in humans.
- the HBs antigen is preferably an HBs antigen contained in an HB vaccine.
- an HBs antigen contained in an HB vaccine for example, in the case of humans, those actually sold as HB vaccines have been approved for safety and efficacy in humans, including healthy individuals, and have been approved. Therefore, according to the dendritic cells having the ability to present HBs antigens of the present invention, it is possible to provide, for example, dendritic cells having the ability to present HBs antigens that can be used safely and effectively in humans.
- the dendritic cells having the ability to present HBs antigen of the present invention can be used not only for the purpose of treating hepatitis B for patients with hepatitis B, but also for healthy individuals. Can also be used for the prevention of hepatitis B.
- hepatitis B of other organisms can be prevented or treated by using ⁇ cells that have been pulsed with an HB vaccine that is safe and effective for that organism.
- the method for producing a dendritic cell having the ability to present HBs antigen according to the present invention includes a step of norsing the dendritic cell with an HBs antigen. According to this, a dendritic cell having HBs antigen presenting ability, which is effective for prevention or treatment of hepatitis B, can be obtained.
- the method for producing dendritic cells having the ability to present HBs antigen of the present invention preferably further includes a step of obtaining the dendritic cells from blood. According to this, it is possible to obtain the dendritic cells having the HBs antigen presenting ability of the present invention from the dendritic cells derived from blood. Moreover, if blood is used, it is possible to obtain ⁇ cells by a relatively simple operation using a conventionally known method or the like. [0030]
- the method of the present invention for producing filamentous cells having the ability to present HBs antigens preferably further comprises a step of collecting the blood from an organism.
- the organism is preferably a human. According to this, it is possible to obtain dendritic cells having the ability to present HBs antigen, which are effective in preventing or treating hepatitis B in humans.
- the HBs antigen is preferably an HBs antigen contained in an HB vaccine. According to this, it is possible to provide a living cell, for example, a human including a healthy person, with a human cell including HBs antigen presenting ability, which can be used safely and effectively and is effective for prevention or treatment of hepatitis B. it can.
- a composition comprising a dendritic cell having HBs antigen presenting ability
- the composition of the present invention comprising the dendritic cells capable of presenting HBs antigens is characterized by containing the dendritic cells capable of presenting HBs antigens of the present invention.
- the dendritic cells having the ability to present HBs antigen of the present invention are used, for example, in a state of being mixed with another substance, a state of being suspended in another substance, or a state of being combined with another substance. be able to.
- the cells having the HBs antigen presenting ability of the present invention are suspended in PBS, physiological saline, RPMI 1640 medium, or the like, or the cells having the HBs antigen presenting ability of the present invention are suspended.
- the dendritic cells having the ability to present HBs antigens of the present invention are used in a mode suitable for the intended use or in a mode in which the effects of the dendritic cells having the ability to present HBs antigens of the present invention are enhanced. It becomes possible.
- composition containing the dendritic cells capable of presenting HBs antigens of the present invention preferably further contains an HB vaccine additive.
- the composition of the present invention containing the dendritic cells capable of presenting HBs antigen examples of the form of the composition include an experimental reagent or an experimental kit. According to this, the dendritic cells having the HBs antigen presenting ability of the present invention can be used in a mode suitable for research, for example, immunological research.
- the composition of the present invention containing a dendritic cell having the ability to present HBs antigen is preferably a pharmaceutical composition. According to this, it has the ability to present HBs antigen of the present invention.
- the obtained dendritic cells can be used in a form suitable for medical treatment, for example, prevention or treatment of hepatitis B.
- the composition of the present invention containing dendritic cells having the ability to present HBs antigen is preferably an immune response-activating preparation.
- the dendritic cells capable of presenting HBs antigens of the present invention can be used in a dosage form suitable for activating an immune response to HBs antigen.
- the composition of the present invention containing the dendritic cells having the ability to present HBs antigen is preferably a cell vaccine.
- the dendritic cells having the ability to present HBs antigen of the present invention can be directly administered into a living body, and an immune response to HBs antigen can be activated.
- the cellular actin is preferably a vaccine for preventing or treating hepatitis B.
- the hepatitis B is prevented or treated by activating the dendritic cells having the ability to present the HBs antigen of the present invention contained in the above-mentioned cell vaccine in vivo to an immune response against the HBs antigen. It becomes possible.
- the method for preventing or treating hepatitis B using ⁇ cells having HBs antigen presenting ability of the present invention is as follows.
- the present invention is also characterized in that the present invention uses a dendritic cell having an HBs antigen presenting ability. According to this, the dendritic cells having the ability to present HBs antigen of the present invention can prevent or treat hepatitis B by activating the immune response to HBs antigen.
- the conventional HB vaccine has been effective in healthy individuals who have failed to respond to the previous HB vaccine, those who are ill with diseases associated with reduced immune competence, and those who are receiving immunosuppressive drugs.
- a person who cannot exert his or her ability can produce an anti-HBs antibody by the method for preventing or treating hepatitis B of the present invention, and can prevent or treat hepatitis B.
- the method for preventing or treating hepatitis B using the dendritic cells having the ability to present HBs antigens of the present invention comprises the step of administering the dendritic cells having the ability to present HBs antigens of the present invention to an organism.
- hepatitis B is predicted by activating the immune response to the HBs antigen in the living cells of the present invention, which is capable of presenting HBs antigen and having the ability to present HBs antigen. Can be prevented or treated.
- the method for preventing or treating hepatitis B of the present invention can exhibit a higher effect than the conventional method for preventing or treating hepatitis B in which an HB vaccine is directly administered to a living body. .
- the organism is preferably a human. According to this, it is possible to prevent or treat hepatitis B in humans.
- the vaccine-pulsed dendritic cells of the present invention are vaccine-pulsed dendritic cells obtained by a method including a step of pulsating dendritic cells with a vaccine.
- vaccine-pulsed dendritic cell refers to a dendritic cell having an antigen-presenting ability obtained by a method including a step of pulsing with a vaccine. To tell.
- the vaccine pulse-shaped cells of the present invention can activate T cells by presenting the antigen epitope contained in the vaccine to T cells, and can enhance an immune response to the antigen. Therefore, according to the present invention, it is possible to provide a vaccine pulsed dendritic cell which is effective in preventing or treating a disease.
- vaccines that are actually sold as vaccines are those that have been approved for safety and efficacy in humans. Therefore, according to the present invention, it is possible to provide, for example, vaccine pulsed cells that can be used safely and effectively in humans. Not only humans but also other organisms can be prevented or treated by using vaccine pulsed cells that have been pulsed with a vaccine that is safe and effective for that organism. .
- the method preferably further comprises a step of obtaining the dendritic cells from blood.
- a step of obtaining the dendritic cells from blood it is possible to provide the pulsed blood cells of the present invention from blood-derived blood cells.
- ⁇ -shaped cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the method may further comprise: It preferably includes a step of collecting the liquid.
- the organism is preferably a human. According to this, human-derived dendritic cells can be obtained, so that the vaccine pulse dendritic cells according to the present invention can be administered to humans. Therefore, according to the present invention, it is possible to provide vaccine pulsed cells that are effective for prevention or treatment of human diseases.
- the vaccine used for the pulse is preferably a vaccine for preventing or treating disease. According to this, it is possible to provide a vaccine pulsed cell that presents an antigen associated with the disease contained in these vaccines. Therefore, the disease can be prevented or treated.
- the vaccine used for the pulse is preferably a hepatitis vaccine.
- hepatitis vaccines include, for example, hepatitis A vaccine, hepatitis B vaccine, and the like.
- those actually sold as hepatitis vaccines have been approved for safety and efficacy in humans, including healthy individuals, and have been approved. Therefore, according to the present invention, it is possible to provide, for example, hepatitis vaccine pulsed cells having the ability to present hepatitis virus antigens that can be safely and effectively used in humans.
- the hepatitis vaccine pulsed cells of the present invention can be used not only for the purpose of treating hepatitis in hepatitis patients and the like, but also for healthy subjects. It can be used for the prevention of hepatitis. It should be noted that not only humans but also other organisms can be used to prevent or treat hepatitis in the organisms by using pulsatile cells pulsed with a safe and effective hepatitis vaccine.
- the hepatitis vaccine is preferably an HB vaccine containing an HBs antigen. According to this, it is possible to provide a vaccine pulsed cell having an HBs antigen presenting ability, which can be safely and effectively used for preventing or treating hepatitis B, for an organism, for example, a human including a healthy person. it can.
- the method for producing vaccine pulsed dendritic cells of the present invention includes a step of pulsing dendritic cells with a vaccine. According to this, vaccine-pulsed dendritic cells effective for prevention or treatment of disease can be obtained.
- the method of the present invention for producing pulsed blood cells preferably further comprises the step of obtaining the blood cells from blood. According to this, it is possible to obtain the vaccine pulsed dendritic cells of the present invention from blood-derived dendritic cells.
- ⁇ ⁇ cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the method for producing vaccine pulsed cells of the present invention further includes a step of collecting the blood from an organism.
- the organism is preferably a human. According to this, it is possible to obtain vaccine pulsed cells effective for prevention or treatment of human diseases.
- the vaccine used for the pulse is preferably a vaccine for preventing or treating disease. According to this, it is possible to provide a vaccine pulsed cell which is effective for prevention or treatment of the above-mentioned disease.
- the vaccine used for the pulse is preferably a hepatitis vaccine. According to this, it is possible to provide hepatitis vaccine pulsed cells having hepatitis virus antigen presenting ability, which can be safely and effectively used for preventing or treating hepatitis, for an organism, for example, a human including a healthy person. it can.
- the hepatitis vaccine is an HB vaccine containing an HBs antigen. According to this, it is possible to provide vaccine pulsed cells having HBs antigen presenting ability, which can be safely and effectively used for preventing or treating hepatitis B, to an organism, for example, a human including a healthy person. it can.
- composition comprising a vaccine pulsed cell
- the composition comprising the vaccine pulsed cells of the present invention is characterized by containing the vaccine pulsed cells of the present invention.
- the vaccine pulse-shaped cells of the present invention can be used, for example, in a state of being mixed with another substance, a state of being suspended in another substance, a state of being combined with another substance, and the like.
- the dendritic cells having the HBs antigen presenting ability of the present invention are suspended in, for example, PBS, physiological saline, RPMI 1640 medium or the like, or the HBs antigen presenting ability of the present invention is present.
- the vaccine pulse-shaped cells of the present invention can be used in a mode suitable for the intended use or in a mode in which the effects of the vaccine pulse-shaped cells of the present invention are enhanced.
- composition containing the vaccine pulsed cells of the present invention further contains a vaccine additive.
- the composition of the present invention comprising the vaccine pulse cells
- the composition is preferably an experimental reagent or an experimental kit.
- the vaccine pulsed cells of the present invention can be used in a mode suitable for research, for example, immunological research.
- the composition of the present invention comprising pulsed pulsatile cells
- the composition is preferably a pharmaceutical composition.
- the vaccine pulse-shaped cells of the present invention can be used in a form suitable for medical treatment, for example, prevention or treatment of disease.
- composition of the present invention comprising the pulse-shaped cells
- the composition is an immune response-active preparation.
- the vaccine pulsed cells of the present invention can be used in a dosage form suitable for activating an immune response to an antigen contained in the vaccine.
- the composition of the present invention comprising the pulsed pulse cells of the vaccine
- the composition is preferably a cellular actin.
- the vaccine pulse-shaped cells of the present invention can be directly administered to a living body, and an immune response to an antigen contained in the vaccine can be activated.
- the cell vaccine is preferably a vaccine for preventing or treating a disease.
- the disease is prevented or treated by activating the immune response to the antigen contained in the vaccine in vivo in the vaccine virus-like cells of the present invention contained in the cytoplasm. It becomes possible.
- the method for preventing or treating diseases using the vaccine pulsed cells of the present invention is characterized by using the vaccine pulsed cells of the present invention.
- the peptide-pulsed dendritic cells of the present invention activate an immune response against the antigen contained in the vaccine.
- the disease can be prevented or treated.
- healthy subjects who have failed to respond to the vaccines used to prevent or treat the above-mentioned diseases or those who are sick with diseases accompanied by reduced immunological ability, or during administration of immunosuppressive drugs By using the method for preventing or treating a disease according to the present invention, a person who can not exert a sufficient effect of a vaccine, such as a human, can produce antibodies, and the disease can be prevented or treated. Will be possible.
- the method for preventing or treating a disease using the vaccine pulse-shaped cells of the present invention includes a step of administering the vaccine pulse-shaped cells of the present invention to an organism.
- the disease can be prevented or treated by activating the immune response to the antigen contained in the vaccine in vivo in the vaccine pulsed cell force of the vaccine of the present invention.
- the method for preventing or treating a disease of the present invention can exhibit a higher effect than a conventional method for preventing or treating a disease by directly administering a vaccine to a living body.
- the organism is preferably a human. According to this, it is possible to prevent or treat human diseases.
- the human pulsed hepatitis B cell of the present invention is a human pulsed hepatitis B virus for preventing or treating hepatitis B in a human
- the vaccine pulsed hepatitis cell is a hepatitis B patient or hepatitis B virus.
- Carrier power Obtained by a manufacturing method comprising a step of obtaining peripheral cells by collecting peripheral blood and obtaining dendritic cells using monocytes isolated from the peripheral blood, and a step of pulsing the dendritic cells with a vaccine.
- Vaccine pulsed cells, wherein the vaccine used for the pulse is a vaccine for preventing or treating hepatitis B.
- the vaccine pulsed cells of the present invention preferably induce Th2, do not induce Thl, and more preferably do not induce CTL.
- the human vaccine pulsed cells of the present invention have the following advantages. Cancer treatment, etc. Done in! / Pull cell therapy! Since the purpose is to induce cytotoxic T cells (CTLs), Th1 induction is promoted, and dendritic cells are activated so as not to induce Th2. In contrast, the human vaccine pulsed dendritic cells of the present invention, for example, induce Th2 and do not induce Thl and CTL, and thus have a completely different mechanism from dendritic cell therapy that has been performed in cancer treatment and the like. .
- CTLs cytotoxic T cells
- the vaccine pulse-shaped cells of the present invention for example, it is possible to produce antibodies without inducing CTL, and it is also possible to cause liver damage (for example, fulminant hepatitis, etc.) due to CTL attack on hepatocytes. Absent. Therefore, the human vaccine pulsed cells of the present invention are extremely useful for hepatitis B patients and hepatitis B virus carriers. It should be noted that the human vaccine northoid cells of the present invention do not induce Thl or CTL.
- the pulse time in the step of pulsing the dendritic cells with a vaccine is preferably, for example, 8 hours to 24 hours.
- the isolated monocytes are co-cultured with GM-CSF and IL 4.
- the method for producing pulsed human cells of the vaccine for humans of the present invention comprises the steps of collecting peripheral blood from a patient with hepatitis B or hepatitis B virus and obtaining monocytes using monocytes isolated from the peripheral blood. Blood-derived human-derived blood cell-shaped cell obtaining step; and pulse step of pulsing the cell-shaped cell with a vaccine to obtain a vaccine pulse cell-shaped cell for prevention or treatment of human hepatitis B.
- the vaccine used in the pulsing step in the pulsing step is a vaccine for preventing or treating hepatitis B.
- the human vaccine pulse dendritic cells obtained by the production method of the present invention it is preferable that humans, for example, induce Th2 and not Thl, and further preferably do not induce CTL. ,.
- the pulse time in the vaccine pulse step is preferably 8 hours to 24 hours.
- isolated monocytes are co-cultured with GM-CSF and IL4.
- IL4 IL4.
- the medicament for the treatment and prevention of human hepatitis B of the present invention is characterized by comprising the above-mentioned human vaccine pulsed cells of the present invention.
- the vaccine pulsed dendritic cell force of the present invention for example, induces Th2 and not Thl, and further does not induce CTL. Since CTL is not induced in this way, according to the medicament of the present invention, fulminant hepatitis is not caused by, for example, hepatic cell attack by CTL.
- vaccines such as hepatitis B patients, as well as healthy persons who have failed to respond to the vaccines that have been used to prevent or treat hepatitis B
- a powerful person who cannot exert sufficient effects will be able to produce antibodies, thereby preventing or treating hepatitis B.
- the hepatitis B includes chronic hepatitis B.
- the dosage form of the medicament for the treatment and prevention of human hepatitis B of the present invention is not particularly limited, but, for example, is preferably administered subcutaneously.
- the method for preventing or treating hepatitis B in humans using the vaccine pulsed human cells for humans of the present invention comprises the steps of: using the vaccine pulsed human cells derived from autologous human dendritic cells for hepatitis B patients or hepatitis B virus carriers.
- a vaccine or pulse hepatitis B virus carrier which is obtained by collecting peripheral blood and using monocytes isolated from the peripheral blood.
- a human vaccine pulse ⁇ cells obtained by a production method including a ⁇ cells acquisition step of obtaining ⁇ cells and a pulsing step of pulsing the ⁇ cells with a vaccine, wherein the vaccine used for the pulse is B It is a vaccine for preventing or treating hepatitis C.
- the human vaccine for human hepatitis B cells may be activated, for example, by inducing Th2 and Th1 It is preferred that it is not induced, and it is further preferred that it does not induce CTL.
- vaccines for not only hepatitis B patients but also healthy persons who have failed to respond to the vaccines used to prevent or treat hepatitis B have been used. People who can not exert sufficient effects can produce antibodies, type B It becomes possible to prevent or treat hepatitis.
- the method of prevention or treatment of the present invention uses the hepatitis B patient or the hepatitis B virus carrier's own dendritic cells, and thus is extremely safe.
- the hepatitis B include chronic hepatitis B.
- the administration form of the human pulsed V-shaped cells is not particularly limited. For example, subcutaneous administration is preferable.
- the vaccine pulsed dendritic cells are obtained by collecting peripheral blood from a hepatitis B patient or a hepatitis B virus carrier, and obtaining dendritic cells using monocytes isolated from the peripheral blood; and A human vaccine pulsed ⁇ cells obtained by a production method including a pulse step of pulsing the ⁇ cells with a vaccine, wherein the vaccine used for the pulse is a vaccine for preventing or treating hepatitis B; And administering the vaccine pulsed cells to a hepatitis B patient or a hepatitis B virus carrier from which peripheral blood has been collected.
- the pulsed human cells for human vaccine of the present invention are used for the treatment or prevention of human hepatitis B, it can be used to prevent or treat hepatitis B as well as hepatitis B patients.
- healthy people who have failed to respond to the vaccine such as healthy volunteers who have failed to respond to the vaccine, will be able to produce antibodies and prevent or treat hepatitis B. Will be possible.
- hepatitis B patients or hepatitis B virus carrier's own cells are used, the safety is extremely high.
- Human vaccine pulse of the present invention pulsatile cell force
- the hepatitis B includes chronic hepatitis B.
- FIG. 1 shows anti-HBs antibody levels before administration of HB vaccine pulsed dendritic cells in Example 1.
- FIG. 2 is a graph showing changes in HLA-DR and CD86 in dendritic cells by the HB vaccine pulse in the above example.
- FIG. 3 is a graph showing changes in the ability of dendritic cells to assist T cell blastogenesis by the HB vaccine pulse in the above example.
- FIG. 4 is a graph showing the effect of HB vaccine pulsed dendritic cells on the proliferation ability of HBs memory T cells using the HBs memory T cells in the above example.
- FIG. 5 is a graph showing the effect of HB vaccine pulsed dendritic cells on anti-HBs antibody-producing ability using HBs memory T cells in the above example.
- FIG. 6 shows test items of a safety test of HB vaccine pulsed cells by a blood biochemical test in the above example.
- FIG. 7 is a graph showing the results of an ALT test in the example.
- FIG. 8 is a graph showing the results of a CRP test in the example.
- FIG. 9 is a graph showing the results of a PT test in the above example.
- FIG. 10 is a graph showing the results of Creatinine test in the above example.
- FIG. 11 is a graph showing the results of a safety test on an autoimmune reaction using a serum biochemical test in the above example.
- Fig. 12 shows changes in anti-HBs antibody levels due to administration of HB vaccine pulsed dendritic cells in the above example.
- FIG. 13 is a graph showing changes in anti-HBs antibody levels due to administration of HB vaccine pulsed dendritic cells in the above example.
- FIG. 14 is a graph showing changes in the anti-HBs antibody level of the HB actin non-responder by the administration of the HB vaccine pulsed dendritic cells in the above example.
- FIG. 15 is a graph showing the results of a safety test on an autoimmune reaction using a serum biochemical test in Example 2.
- FIG. 16 is a graph showing a change in anti-HBs antibody value due to administration of HB vaccine pulsed dendritic cells in Example 3.
- a dendritic cell having the ability to present HBs antigen The dendritic cells having the ability to present HBs antigen according to the present embodiment can be obtained by a method including a step of norsing the dendritic cells with HBs antigen. According to the dendritic cell having the ability to present HBs antigen according to the present embodiment, it is possible to provide a dendritic cell having the ability to present HBs antigen, which is effective in preventing or treating hepatitis B.
- pulsedritic cells with an antigen means that the dendritic cells take in an antigen and are degraded in the dendritic cells, and the degraded antigen is converted into a peptide. It means to be able to present.
- the antigen and dendritic cells are allowed to coexist in the presence of an appropriate cytodynamic force or the like. Culture method.
- the method for obtaining dendritic cells is not particularly limited, as long as it finally obtains dendritic cells capable of taking in an antigen and presenting this antigen, and various techniques can be used.
- blood cells can be obtained. Specifically, for example, a method of inducing differentiation of dendritic cells from blood containing dendritic cell precursor cells or a method of directly separating dendritic blood cells using a method known to those skilled in the art. Can be used.
- the method of inducing CD34-positive progenitor cells in bone marrow cells, cord blood or peripheral blood mainly using GM CSF and TNF- ⁇ , and mainly using cord blood mononuclear cells or peripheral blood mononuclear cells
- GM-CSF and IL-4 are used for induction
- GM-CSF and IFN- ⁇ are mainly used for peripheral blood mononuclear cells, and direct isolation from peripheral blood mononuclear cells.
- the method for obtaining these dendritic cells can further include a step of collecting blood from an organism, if necessary.
- the organism is not particularly limited depending on the possibility of infecting hepatitis ⁇ , but is preferably, for example, an organism capable of infecting hepatitis ⁇ .
- the organism that can be infected with hepatitis ⁇ ⁇ preferably includes an organism that can be naturally infected with hepatitis ⁇ and an organism that can artificially infect hepatitis ⁇ .
- examples of organisms that can be naturally infected with the hepatitis ⁇ include those that artificially infect the hepatitis ⁇ , such as primates such as humans and chimpanzees, and ducks such as woodchuck and pekin duck.
- examples of organisms that can be used include squirrels, rats, ducks, geese, herons, vines, and mice. Etc.
- the effect of using the present invention when the organism is a human is great.
- Examples of a method for obtaining a dendritic cell without using blood include a method for inducing differentiation of an ES cell to obtain a dendritic cell. Specifically, for example, by culturing ES cells established inside the blastocyst together with an appropriate feeder cell or cytodynamic force, the ES cells can be divided into dendritic cells. Can be guided.
- a medium for culturing dendritic cells is described. Induction of differentiation of dendritic cells from progenitor cells into dendritic cells, survival of dendritic cells, and antigen-mediated There is no particular limitation as long as the pulse of dendritic cells is not inhibited.
- RPMI 1640 medium or the like can be used. Further, RPMI 1640 medium is preferable.
- cytoidin can be used for induction of dendritic cells.
- the cytodynamic force used for inducing dendritic cells is not particularly limited as long as it does not inhibit induction of differentiation into dendritic cells, survival of dendritic cells, pulse of dendritic cells by antigen, etc., for example, GM-CSF , TNF- ⁇ , IL-4, IFN- ⁇ and the like can be used.
- the mode of the HBs antigen is not particularly limited as long as it can be finally presented by dendritic cells, and may be an antigen of a complete protein or a peptide antigen.
- the HBs antigen according to the present embodiment can be used, for example, in a form in which it is combined with various substances and liquids. Specifically, for example, HBs antigen is introduced into dendritic cells using a phospholipid bilayer membrane such as ribosome, or HBs antigen is suspended in a buffer such as PBS or a medium such as RPMI 1640 medium. It can be turbid and introduced into ⁇ cells.
- a buffer such as PBS or a medium such as RPMI 1640 medium. It can be turbid and introduced into ⁇ cells.
- the timing of adding the HBs antigen is not particularly limited as long as the HBs antigen can be presented by dendritic cells. For example, it is added after differentiation of dendritic cells is induced. be able to.
- HBs antigen can be added at the time of induction of shunting and cultured together.
- the HBs antigen norse time is not particularly limited as long as the HBs antigen can be presented by dendritic cells as a result, and is preferably, for example, 8 hours to 24 hours.
- the HBs antigen is preferably an HBs antigen contained in an HB vaccine.
- Vaccines include, for example, live vaccines, inactive dani vaccines, toxoids, etc.
- a live vaccine is, for example, a vaccine that breeds live viruses and bacteria with reduced pathogenicity.
- the inactivated vaccine is, for example, a vaccine produced by purifying virus particles, bacterial cells, and the like, and treating with heat or a drug such as formalin to eliminate or detoxify the pathogenicity.
- the toxoid refers to, for example, a product obtained by removing and purifying only the fungal toxin and then detoxifying formalin without loss of immunogenicity.
- the type of HB vaccine in the present embodiment is not limited as long as it contains the HBs antigen, but the HB vaccine currently licensed and used for human use in Japan is It is classified as the Inactivator vaccine.
- an HB vaccine that is an inactivated vaccine for example, a recombinant precipitated hepatitis B vaccine or a precipitated hepatitis B vaccine can be used.
- Recombinant precipitated hepatitis B vaccine includes, for example, the active ingredient of a hepatitis B virus by inserting a portion corresponding to the HBs antigen of DNA of the hepatitis B virus into DNA of yeast, animal cells and the like, and expressing it.
- HBs antigens can be prepared and a vaccine prepared by adding an aluminum gel as an immune enhancer can be used.
- animal cells for example, vaccines prepared using CHO cells can be used.
- the precipitated hepatitis B vaccine for example, a vaccine prepared by purifying an HBs antigen produced by animal cells or the like, and then preparing an aluminum gel can be used.
- an animal cell for example, a vaccine prepared using huGK-14 cells can be used.
- the method for producing dendritic cells having HBs antigen presenting ability includes a step of pulsing dendritic cells with HBs antigen. According to this, it is possible to obtain dendritic cells having the ability to present HBs antigen, which are effective in preventing or treating hepatitis B.
- the production method preferably further includes the step of obtaining the blood cells.
- the dendritic cells having the HBs antigen presenting ability of the present invention can be obtained from the dendritic cells derived from blood.
- ⁇ cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the production method preferably further includes a step of collecting the blood from an organism. That's right.
- the organism is preferably a human. According to this, it is possible to obtain dendritic cells having HBs antigen presenting ability, which are effective for prevention or treatment of human hepatitis B.
- the HBs antigen is preferably an HBs antigen included in an HB vaccine! According to this method, it is possible to provide, to an organism, for example, a human including a healthy person, a dendritic cell having an HBs antigen presenting ability, which can be used safely and effectively for preventing or treating hepatitis B. Monkey
- composition according to the present embodiment preferably contains the dendritic cells having the ability to present HBs antigen according to the present embodiment.
- composition according to the present embodiment preferably further contains an HB vaccine additive.
- the composition according to the present embodiment further includes a carbohydrate added to the HB vaccine
- the additive power of the HB vaccine is somewhere in the entire composition according to the present embodiment. Let's say the state that is included. That is, the location where the HB vaccine additive is contained is not particularly limited, and may be anywhere such as outside, inside, or on the cell membrane in the composition according to the present embodiment.
- the HBs antigen contained in the HB vaccine was used as the HBs antigen to obtain a dendritic cell having the HBs antigen presenting ability according to the present embodiment. Can be determined.
- HB vaccine additive examples include preservatives, antibiotics, stabilizers, preservatives, immunopotentiators, buffers, isotonic agents and the like. Specific examples include thimerosal, potassium aluminum sulfate, sodium hydroxide, aluminum chloride, acetic acid, sodium acetate, sodium chloride and the like. The HB vaccine additive is not limited to these.
- a known analysis method can be used. Specific examples include, for example, separation analysis and quantitative analysis using various chromatographs, and structural analysis using infrared spectroscopy, nuclear magnetic resonance analysis, mass spectrometry, elemental analysis, and the like.
- the composition according to the present embodiment is preferably an experimental reagent or an experimental kit.
- the dendritic cells having the ability to present HBs antigen according to the present embodiment can be used in a manner suitable for various studies. Research fields that can be used include, for example, research on signal transduction mechanisms related to immune response, immune tolerance, and production of cytodynamic force, and research on immunotherapy using dendritic cells. Further, it can be used for the purpose of, for example, research relating to the prevention or treatment of hepatitis B, for example, screening for genes, RNA, peptides, proteins, compounds, drugs, cytotoxicity, and the like.
- the composition according to the present embodiment is preferably a pharmaceutical composition.
- the pharmaceutical composition according to the present embodiment can be used, for example, in a mode in which it is directly administered into a living body or in a mode in which it is mixed with other substances or cells outside a living body.
- composition according to the present embodiment is preferably an immune response active preparation.
- the immune response activating preparation according to the present embodiment can be used, for example, in a form in which it is directly administered into a living body or in a form in which it is mixed with other substances or cells outside a living body.
- the immune response activating preparation according to the present embodiment is mixed with a T cell, and the HBs antigen epitope is presented to the T cell.
- T cells can be used after being administered in vivo.
- Examples of the mode of directly administering the composition according to the present embodiment into a living body include injection and infusion as a cell vaccine.
- the cell vaccine is preferably a vaccine for preventing or treating hepatitis B.
- Examples of a place where the composition according to the present embodiment is directly administered to a living body include, for example, intravenous administration, intraarterial administration, intrathoracic administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, and intramuscular ( For example, intrahepatic administration and lymph node administration. Subcutaneous injection is preferred because of the simplicity of administration.
- the dendritic cells having the ability to present HBs antigen according to the present embodiment can be used, for example, for preventing or treating hepatitis B.
- the prevention or treatment of hepatitis B using ⁇ cells having the ability to present HBs antigen can be used, for example, in combination with a conventional method for preventing or treating hepatitis B.
- the prevention or treatment of hepatitis B using H cells having the ability to present HBs antigen according to the present embodiment includes the step of administering to the organism an N cells having the ability to present HBs antigen.
- the organism include organisms that can be infected with hepatitis B as described above.
- the organism from which the dendritic cells are derived and the organism to be administered may be the same or different.
- the dendritic cells according to the present embodiment can be administered to the removed autologous body, or to the non-autologous body that matches the degree to which the histocompatible antigen can be administered. It is also possible to do so.
- the organism is preferably a human.
- the origin of the dendritic cell is preferably a dendritic cell derived from a related donor. If autologous cells are used, it is not necessary to consider the compatibility of the HLA type, and thus, more preferably, they are dendritic cells derived from the subject of the administration.
- the dendritic cells having the ability to present HBs antigen according to the present embodiment can be used in a mode of direct administration into a living body, or can be mixed with T cells in vitro to activate T cells.
- the T cells can be used in such a form that they are administered in vivo.
- T cells are single cells, once they function, they die and disappear in a short time. Therefore, in order to prevent and treat hepatitis B, it is necessary to repeatedly administer T cells at a high frequency.
- dendritic cells also act on naive T cells, HBs memory T cells, and B cells and repeatedly stimulate them, resulting in a long and powerful effect. From the above, it is considered that it is more preferable to use the dendritic cells having the ability to present HBs antigen according to the present embodiment in such a manner that they are directly administered to a living body.
- the dendritic cells having the ability to present HBs antigen according to the present embodiment and the effects thereof will be described.
- This use example can be applied to the prevention or treatment of hepatitis B.
- the use example is not limited to the following cases, and the usage of the dendritic cells according to the use example may be various without departing from the scope of the present invention. Can be changed.
- HB vaccine Approximately 10% of healthy individuals are non-responders to the HB vaccine, and it is known that administration of the HB vaccine cannot produce anti-HBs antibodies. I have. Since hepatitis B is transmitted via blood, it is thought that the need for anti-HBs antibodies is particularly high for healthcare workers and the like. However, even in these people, non-responders of the HB vaccine are not small.
- the dendritic cells capable of presenting HBs antigens enable the current HB vaccine non- responder to produce anti-HBs antibodies, thereby preventing infection with hepatitis B. .
- the HB vaccine currently used for the prevention of hepatitis B usually requires three inoculations at regular intervals.
- administration of the dendritic cells capable of presenting HBs antigen according to the present embodiment once gives not only non-responders to HB vaccine but also healthy subjects to which HB vaccine is effective. (Responder) anti-HBs antibody levels could also be increased. Therefore, the dendritic cells having the ability to present HBs antigens according to the present embodiment can be used not only for non-responders of HB vaccine but also for responders of HB vaccine as a new means for preventing hepatitis B. It is possible to reduce the number of inoculations and the economic burden.
- the conventional HB vaccine cannot exert sufficient effects on people with reduced immunity, such as HIV patients, liver disease patients, dialysis patients, obese people, and smokers. .
- Such people may also use the dendritic cells capable of presenting HBs antigen according to the present embodiment. It is thought that this makes it possible to produce anti-HBs antibodies.
- hepatitis B has been mainly treated with antiviral agents.
- a long-term administration of an antiviral agent causes a high frequency of mutant viruses in which the antiviral agent is ineffective.
- the hepatitis B virus load rose again, and there was a risk of causing hepatitis criticism.
- the dendritic cells having the ability to present HBs antigen according to the present embodiment will allow the patient to produce an anti-HBs antibody.
- the dendritic cells having the ability to present HBs antigens according to the present embodiment were administered, for example, once every 3 to 6 months, whereby an anti-HBs antibody of 10 mL or more was obtained. It is expected that the value can be maintained.
- the use of the dendritic cells having the ability to present HBs antigens according to the present embodiment makes it possible to significantly reduce the frequency of administration as compared with the use of anti-HBs human immunoglobulin. It is thought that the economic burden can be greatly reduced.
- the HB vaccine that has existed conventionally is a preventive vaccine for hepatitis B, and a therapeutic vaccine for hepatitis B has been used only for trial purposes.
- dendritic cells having the ability to present HBs antigens produced using the HB vaccine according to the present embodiment differ from the conventional HB vaccine only in preventing hepatitis B. And made it possible to use it for treatment. This is currently used in practice
- the use of the HB vaccine which has been recognized for its safety and efficacy, can be broadened, and a new use mode that enhances the effect of the HB vaccine that has existed so far can be said to have been found.
- the dendritic cells having the ability to present HBs antigen according to the present embodiment have a wide range of uses and great advantages.
- Vaccine-pulsed ⁇ cells are obtained by a method including a step of pulsing ⁇ cells with a vaccine. According to this, it is possible to provide an actin-pulsed dendritic cell which is effective in preventing or treating a disease.
- the method preferably further includes the step of obtaining blood dendritic cells.
- the method further includes a step of collecting the blood from an organism.
- the organism is a human.
- peripheral blood of a patient with chronic hepatitis B or a carrier is collected, and dendritic cells are obtained using monocytes isolated from the peripheral blood.
- peripheral blood can be safely and easily collected repeatedly.
- the time of addition of the vaccine is not particularly limited as long as the antigen contained in the vaccine can be presented by dendritic cells. can do.
- a vaccine can be added at the time of induction of shunting and cultured together.
- the pulse time of the vaccine is not particularly limited as long as the antigen contained in the vaccine can be presented by dendritic cells.
- the 8-hour force is preferably 24 hours.
- the vaccine is not particularly limited as long as the antigens contained in the vaccine can be presented by dendritic cells, and examples thereof include a live vaccine, an inactivated vaccine, a toxoid, and an antitoxin. Can be used.
- the form of the vaccine is not particularly limited as long as the antigen contained in the vaccine can be presented by dendritic cells, and examples thereof include a liquid vaccine, a precipitated vaccine, and a lyophilized vaccine. Can be used.
- vaccines examples include pertussis vaccine, diphtheria toxoii. Tetanus toxoid, polio vaccine, measles vaccine, rubella vaccine, Japanese encephalitis vaccine
- Influenza vaccine, tuberculosis vaccine such as BCG vaccine, mumps vaccine, varicella vaccine, varicella vaccine, hepatitis A vaccine, hepatitis B vaccine, pneumococcal vaccine, yellow fever vaccine, rabies vaccine, cholera vaccine, Weil's disease autumn mixed vaccine, habu Examples include antitoxin, viper antitoxin, plague vaccine, MMR vaccine, typhoid fever vaccine, bacterium conjugated with phnolenzenza b, meningococcal vaccine, dysentery vaccine, and malaria vaccine.
- the vaccine that can be used in the present embodiment is not limited to those exemplified here.
- the vaccine used for the norse is preferably a vaccine for preventing or treating a disease.
- the vaccine used for the pulse is preferably a hepatitis vaccine. It is preferable that the hepatitis vaccine is, for example, an HB vaccine containing an HBs antigen.
- the method for producing vaccine pulsed dendritic cells according to the present embodiment includes a step of norsing the dendritic cells with a vaccine. According to this, it is possible to obtain vaccine pulse ⁇ cells which are effective for prevention or treatment of disease.
- the production method preferably further includes the step of obtaining the blood cells.
- ⁇ cells of the present invention can be obtained by a relatively simple operation using a conventionally known method or the like.
- the production method further includes a step of collecting the blood from an organism.
- the organism is preferably a human. According to this, it is possible to obtain vaccine pulsed ⁇ cells that are effective for prevention or treatment of human diseases.
- the vaccine used for the pulse is preferably a vaccine for preventing or treating a disease. According to this, it is possible to provide a vaccine pulsed cell effective for prevention or treatment of the above-mentioned disease.
- the vaccine used for Norse is preferably a hepatitis vaccine.
- a hepatitis vaccine pulse-forming cell having hepatitis virus antigen presenting ability which is effective for prevention or treatment of hepatitis, which can be safely and effectively used for living organisms, for example, humans including healthy persons. Vesicles can be provided.
- the hepatitis vaccine is, for example, preferably an HB vaccine containing an HBs antigen.
- a pulsed hepatitis cell having the ability to present HBs antigen, which is effective for prevention or treatment of hepatitis B and which can be used safely and effectively for living organisms, for example, humans including healthy persons, is provided. be able to.
- composition comprising vaccine pulsed cells
- composition according to the present embodiment preferably contains the vaccine pulsed cells according to the present embodiment.
- composition according to the present embodiment preferably further contains a vaccine additive.
- the composition according to the present embodiment further contains a vaccine additive
- the vaccine additive power is contained anywhere in the entire composition according to the present embodiment. Let's say you are in a state. That is, the place where the vaccine additive is contained is not particularly limited, and may be anywhere such as outside, inside, or on the cell membrane of the filamentous cell in the composition according to the present embodiment.
- the composition according to the present embodiment contains a vaccine additive, it becomes possible to determine that the vaccine pulsed dendritic cells according to the present embodiment have been obtained using the antigen contained in the antigen as the antigen. .
- vaccine additives include preservatives, antibiotics, stabilizers, preservatives, immunopotentiators, buffers, isotonic agents, coloring agents, and the like. Specific examples include thimerosal and formalin as preservatives, erythromycin, erythromycin ratatobionate, kanamycin sulfate and the like as antibiotics, and other additives.
- Other additives include, for example, purified sucrose, sodium L-glutamate, gelatin, lactose, potassium glutamate, D-sorbitol, human serum albumin, polysorbate 80, glycine, glucose, sodium hydroxide, sodium potassium aluminum sulfate, and salts.
- composition according to the present embodiment is preferably an experimental reagent or an experimental kit.
- the vaccine pulsed cells according to the present embodiment can be used in a form suitable for various studies.
- Research fields that can be used include, for example, research on the signal transmission mechanism related to the disease and research on immunotherapy using dendritic cells. In addition, it can also be used for the purpose of, for example, research relating to the prevention or treatment of the disease, for example, screening for genes, RNA, peptides, proteins, compounds, drugs, cytotoxicity, and the like.
- the composition according to the present embodiment is preferably a pharmaceutical composition.
- the pharmaceutical composition according to the present embodiment can be used, for example, in a mode in which it is directly administered into a living body or in a mode in which it is mixed with other substances or cells outside a living body.
- composition according to the present embodiment is preferably an immune response-activating preparation.
- the immune response activating preparation according to the present embodiment can be used, for example, in a form in which it is directly administered into a living body or in a form in which it is mixed with other substances or cells outside a living body.
- composition according to the present embodiment in vitro, for example, an antigen contained in a vaccine obtained by mixing the immune response activating preparation according to the present embodiment with T cells is used.
- a method of activating a T cell by presenting a peptide to the T cell can be mentioned.
- the T cells can be used after being administered in vivo.
- Examples of the mode of directly administering the composition according to the present embodiment into a living body include injection and infusion as a cell vaccine.
- the cell vaccine is preferably a vaccine for preventing or treating a disease.
- Examples of the place where the composition according to the present embodiment is directly administered to a living body include, for example, intravenous administration, intraarterial administration, intrathoracic administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, and intracellular administration (for example, Administration) and lymph node administration. Subcutaneous injection is preferred because of the simplicity of administration.
- the vaccine pulsed cells according to the present embodiment can be used for prevention or treatment of disease.
- diseases include hepatitis B and chronic hepatitis B.
- the vaccine pulsed cells according to the present embodiment can be used, for example, in combination with a conventional method for preventing or treating the disease.
- the prevention or treatment of the disease according to the present embodiment preferably includes a step of administering the vaccine pulsed cells to an organism.
- the organism include an organism that can be infected with the disease. If the rejection can be suppressed, the organism from which the dendritic cells are derived and the organism to be administered may be the same or different.
- the dendritic cells according to the present embodiment can be administered to the removed autologous body or can be administered to a non-autologous body to which the histocompatible antigen can be administered. It is also possible to administer.
- the organism is preferably a human.
- the origin of the dendritic cell is preferably a dendritic cell derived from a related donor. If autologous cells are used, it is not necessary to consider the compatibility of the HLA type, and thus, more preferably, they are dendritic cells derived from the subject of the administration.
- the vaccine pulse-shaped cells according to the present embodiment can be used in a form directly administered to a living body, or mixed with T cells in vitro to activate T cells.
- the T cells can be used in a mode in which the T cells are administered in vivo.
- T cells are effector cells, they once function and die and disappear in a short time. Therefore, in order to prevent and treat a disease, it is necessary to repeatedly administer T cells at a high frequency.
- dendritic cells also act on naive T cells, memory T cells, and B cells and repeatedly irritate them, resulting in a long and powerful effect. From the above, it is considered that it is more preferable to use the vaccine pulse-shaped cells according to the present embodiment in such a manner that the cells are directly administered to a living body.
- the present usage example is not limited to the following cases, and various changes can be made to the usage of the dendritic cells according to the present usage example without departing from the gist of the present invention.
- ⁇ cells are pulsed using a substance extracted from cancer cells.
- the extracted material is generally a mixture of many types of materials. Therefore, it is considered that the dendritic cells pulsed using the cell extract were pulsed by various antigens in the cell extract.
- the dendritic cells treated in such a manner represent a population of various types of dendritic cells having antigen-presenting ability, including antigens that cannot be identified or are not related to disease! It is believed that there is.
- the dendritic cells thus produced are not allowed to be administered to healthy individuals who are already allowed to use for the treatment of patients who have already suffered from diseases in the field of cancer treatment and the like. Therefore, it is impossible to use dendritic cells pulsed with a cell extract for healthy persons to prevent disease.
- the vaccine-pulsed dendritic cells in the present embodiment can be prepared by pulsing dendritic cells using a vaccine.
- the vaccines that are actually sold are those that have been approved for safety and efficacy in humans, including healthy individuals, and have been approved.
- the vaccine-pulsed dendritic cells according to the present embodiment can be used not only for patients for the treatment of diseases but also for healthy people for the prevention of diseases.
- the vaccine pulsed cells according to the present embodiment can be used for the treatment of tuberculosis.
- vaccine-pulsed dendritic cells according to the present embodiment vaccine-null dendritic cells obtained by a method including a step of pulsing with a tuberculosis vaccine such as a BCG vaccine can be used. According to this, it is expected that the frequency of occurrence of drug-resistant bacteria as described above can be reduced, which is considered to be a great advantage in the treatment of tuberculosis. For other diseases, the same effect may be expected by using vaccine pulsed dendritic cells for the treatment, which is expected to be a great advantage for the treatment of the disease.
- a gene encoding an antigen is incorporated into a plasmid vector or the like and transfected, or a virus vector is used.
- a method of expressing a target antigen in dendritic cells by integrating the cells and infecting them.
- these genetically engineered dendritic cells may be used to treat patients who are sick, but are not intended to prevent disease in healthy individuals. It is allowed to use.
- the vaccine pulsed cells in the present embodiment can be used not only as a vaccine for treating a disease against a patient but also as a vaccine for preventing a disease from a healthy person.
- the vaccine pulse-shaped cells according to the present embodiment are directly administered to a living body, or T cells are activated in vitro by mixing with T cells to activate the T cells in vivo.
- T cells are activated in vitro by mixing with T cells to activate the T cells in vivo.
- the vaccine pulsed cells according to the present embodiment have wide applications and great advantages. Further, it is considered that the prevention or treatment of a disease using the vaccine pulsed dendritic cells according to the present embodiment is completely different from conventional dendritic cell therapy.
- the mononuclear cells obtained in (3) were counted, and 2 mL was added to a 35 mm dish at a cell density of 2 ⁇ 10 6 to 2 ⁇ 10 7 ZmL.
- the medium used was RPMI 1640 medium (manufactured by Nipro Corporation) in which the autologous serum of each subject obtained in (2) was prepared at a concentration of 1 to 5%.
- the culture was performed in a dedicated culture room at 37 ° C, 5% CO concentration and 75% air.
- adherent cells were separated according to the following procedure. First, the dish was taken out of the culture room and left still in a clean bench for 5 minutes. Thereafter, the dis h was tilted obliquely, and the culture solution was slowly applied to the whole adherent cells for washing to remove lymphocytes.
- (6) The adherent cells (monocytes) obtained in (5) were placed on one dish, and GM-CSF (produced by PROTEC EC) was added in 800 UZmL, IL-4 (protech EC) was cultured in 500 UZmL and 2 mL of RPMI 1640 medium supplemented with 1-5% autologous serum for 4 days.
- GM-CSF produced by PROTEC EC
- IL-4 protech EC
- HB vaccine r-HB vaccine "Mitsubishi”: manufactured by Mitsubishi Pharma Corporation
- composition 20 g of HBs antigen, 0.01 wZv% of thymella, 0.01 g of Zw%, 5.2 g of potassium aluminum sulfate (each per mL))
- HB vaccine pulse-like cells Culture is performed at 37 ° C, 5% CO concentration, and 75% air in a dedicated culture room.
- the other dendritic cells were cultured as a negative control without the addition of the HB vaccine.
- HB vaccine pulsed cells were recovered from the dish.
- the collected cells were mixed with PBS and centrifuged at 1500 rpm for 5 minutes at 4 ° C, and the supernatant was discarded. This operation was repeated five times to sufficiently wash the dendritic cells.
- the obtained dendritic cells were added to 500 L of PBS. In addition, the same operation was performed for negative control ⁇ cells.
- Anti-HBs antibody was measured before administration of HB vaccine pulsed dendritic cells.
- blood was collected from five subjects (healthy volunteers who had already received repeated administration of the HB vaccine), and serum from each subject was obtained using the same method as in Experimental Example 1 (2).
- serum was obtained using the same method as in Experimental Example 1 (2).
- the anti-HBs antibody level was measured by the CLIA method. The results are shown in Figure 1. As shown in Figure 1, of the five subjects, two could produce anti-HBs antibodies (anti-HBs antibody positive, responder), and three could not produce anti-HBs antibodies (anti-HBs antibody negative, non- -Responder);
- the HB vaccine pulsed dendritic cells obtained in Experimental Example 2 and the non-denatured dendritic cells were collected by centrifugation at 1500 rpm at 5 ° C. for 5 minutes.
- the collected cells were washed with FCM PBS (pH 7.22: Gibconed earth), and collected by centrifugation again at 5 ° C and 1500 rpm for 5 minutes.
- FIG. 2 shows the results of the analysis.
- the horizontal axis in FIG. 2 shows the analyzed surface antigen, and the vertical axis shows the relative concentration of the surface antigen.
- the results indicate that HB-vaccine pulsed dendritic cells have 1.2-fold higher HLA-DR expression and 1.6-fold higher CD86 expression than non-pulsed dendritic cells. I was helping. These results indicated that the HB vaccine pulsed cells were mature.
- MACS-Buffer is added to the mononuclear cells per 1 ⁇ 10 7 to make 80 ⁇ l, and further 20 L of MACS anti-hapten antibody-labeled microbeads are added, and the mixture is placed at 6 to 12 ° C for 15 minutes. Mixed. Next, the MACS-Buffer was washed and the supernatant was removed. Subsequently, 500 ⁇ L of MACS-Buffer was added to the mononuclear cells per 1 ⁇ 10 7 cells, depletion was performed by the AutoMACS Deplete program, and T cells were collected.
- FIG. 3 shows the results of evaluation of the uptake ability using a ⁇ -ray counter (LS6500: manufactured by Beckman).
- the vertical axis in FIG. 3 shows the ability to take in thymidine, and the horizontal axis shows the cases (a) and (b) shown in (3) from the left.
- Example 1 A 60-mL blood sample was collected from each subject (a healthy volunteer who had already repeatedly received the HB vaccine and who was an HB vaccine responder) .
- Examples 1 (1) and 5 T cells were collected using the method of (2). (Hereinafter, this T cell is referred to as "HBs memory T cell.")
- ⁇ cells were collected using the method of Experimental Example 1 and divided into two.
- One dendritic cell was used as the HB vaccine pulsed dendritic cell using the method of Experimental Example 2, and the other dendritic cell was not pulsed with the HB vaccine and used as a negative control.
- FIG. 5 shows the anti-HBs antibody value
- the horizontal axis shows the cases of (a), (b), (c) and (d) described in (2) from the left. From these results, it was not possible to produce anti-HBs antibody when HB vaccine or non-pulsed dendritic cells were mixed, but anti-HBs antibody was not mixed when HB vaccine pulsed dendritic cells were mixed. It was found that 15-56 mIUZmL could be produced.
- FIG. 7 to 10 show the results of the ALT, CRP, PT, and Creatinine tests.
- the horizontal axis indicates the number of days since administration, and the vertical axes indicate test items and their values. Based on these results, all five subjects who received the HB vaccine pulsed dendritic cells showed no abnormalities in blood biochemical tests. Therefore, HB vaccine pulsed cells were found to be safe.
- Serum was collected using the method of Experimental Example 1 (2), and the anti-HBs antibody level was measured by the CLIA method.
- FIG. 12 is a graph obtained by numerically plotting the values in the graph of FIG.
- FIG. 14 is a graph showing changes in anti-HBs antibody levels in subjects who are non-responders of the HB vaccine.
- the results in Figures 12 and 13 show that a single administration of the HB vaccine Norse ⁇ cells enabled the production of two human anti-HBs antibodies in three subjects who were non-responders of the HB vaccine. Was. Anti-HBs antibody levels also increased in two subjects who were HB vaccine responders.
- each subject was subjected to a brick test on their own dendritic cells. As a result, the brick test was negative in all subjects.
- each subject received 450 ⁇ L of the HB vaccine pulsed dendritic cells subcutaneously. After administration, the subject had no change in subjective symptoms.
- FIG. 15 shows the results of ALT, CRP, PT, and WBC tests of one hepatitis B patient among the above subjects.
- the horizontal axis indicates the number of days from administration, and the vertical axis indicates the test items and their values. Therefore, it was shown that HB vaccine pulsed cells are safe for hepatitis B patients.
- HB vaccine pulsed ⁇ cells were subcutaneously administered at 450 / zL at 2 weeks and 6 weeks after the administration, respectively, to hepatitis B patients.
- Serum was collected from the subject, and the serum was used to measure anti-HBs antibody levels by the CLIA method (weeks 0, 2, 6, 10, 14, 18, and 22).
- Figure 16 shows the results. As shown in the figure, HBs antibody was produced after the first administration (week 0), and the amount of HBs antibody increased even after the third administration (week 6). No increase in liver function tests and no increase in transamylase were observed during this measurement period.
- the vaccine pulsed cells of the present invention can produce HBs antibodies without inducing CTL. I got it. Usually, when CTL is induced, it is also a force that transamylase rises. The mechanism by which this CTL is not induced is unknown. The composition of the HB vaccine used in the pulse is thought to be closely related to the mechanism by which this CTL is not induced. In addition, the vaccine-nodular cells of the present invention can induce HBs antibody production even in hepatitis B patients, indicating that they induce mainly humoral immunity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006512091A JP4852702B2 (ja) | 2004-04-06 | 2005-04-05 | 抗原パルスして得られた樹状細胞 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-112261 | 2004-04-06 | ||
JP2004112261 | 2004-04-06 | ||
JPPCT/JP2004/013321 | 2004-09-13 | ||
PCT/JP2004/013321 WO2005100547A1 (ja) | 2004-04-06 | 2004-09-13 | 抗原パルスして得られた樹状細胞 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005097976A1 true WO2005097976A1 (ja) | 2005-10-20 |
Family
ID=35125067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006679 WO2005097976A1 (ja) | 2004-04-06 | 2005-04-05 | 抗原パルスして得られた樹状細胞 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005097976A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10537639B2 (en) | 2014-08-28 | 2020-01-21 | Pci Biotech As | Compound and method |
-
2005
- 2005-04-05 WO PCT/JP2005/006679 patent/WO2005097976A1/ja active Application Filing
Non-Patent Citations (8)
Title |
---|
AKBAR S. ET AL.: "Production, theraeutic effect and mechanism of action of a vaccine containing antigen-pulsed dendritic cells fpr treatment of chronic hepatitis B virus infection.", HEPATOLOGY, vol. 36, no. 4, 2002, pages 301A - 553 * |
BOCHER W. ET AL.: "Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infectoion.", EUR. J. IMMUNOL., vol. 31, no. 7, 2001, pages 2071 - 2079, XP002904149, DOI: doi:10.1002/1521-4141(200107)31:7<2071::AID-IMMU2071>3.0.CO;2-D * |
FURUKAWA S. ET AL.: "Men'ei Yokusei Jotai deno Jujo Sabo o Mochiita HBs Kotai Sanseiho no Kaihatsu.", THE JAPANESE SOCIETY FOR IMMUNOLOGY SOKAI.GAKUJUTSU SHUKAI KIROKU, vol. 33, 5 November 2003 (2003-11-05), pages 294 * |
FURUKAWA S. ET AL.: "Men'eki Yokusei Jotai deno Jujo Saibo o Mochiita HBs otai Sanseibo no Kaihatsu.", ACTA HEPATOLOGICA JAPONICA, vol. 44, no. 3, 20 October 2003 (2003-10-20), pages A491 * |
ONCHI S. ET AL.: "Jujo Saibo to Kanshikkan no Chiryo.", MINOPHAGEN MEDICAL REVIEW., vol. 49, no. 3, 20 May 2004 (2004-05-20), pages 163 - 170, XP002994486 * |
ONCHI S. ET AL.: "Jujo Sano to kanshikkan no Men'eki Byotai Oyobi Chiryo.", JAPANESE JOURNAL OF CHINICAL IMMUNOLOGY, vol. 27, no. 2, 30 April 2004 (2004-04-30), pages 64 - 76 * |
ONCHI S. ET AL.: "Virus-sei Kan?en no Byotai Keisei ni Okeru Jujo Saibo no Yauwari.", GENDAI IRYO, vol. 35, no. 8, 2003, pages 1833 - 1839 * |
STOBER D. ET AL.: "Dendritic cells pulsed with exogenous hepatitis B surface antigen particles effciently present epitopes to MHC clas I-restricted cytotoxic T cells.", EUR. J.IMMUNOL., vol. 32, no. 4, 2002, pages 1099 - 1108 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10537639B2 (en) | 2014-08-28 | 2020-01-21 | Pci Biotech As | Compound and method |
JP2020182486A (ja) * | 2014-08-28 | 2020-11-12 | ピーシーアイ バイオテック エイエス | 化合物および方法 |
JP7079819B2 (ja) | 2014-08-28 | 2022-06-02 | ピーシーアイ バイオテック エイエス | 化合物および方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10806777B2 (en) | Method for allogeneic cell therapy | |
JP2001520509A (ja) | 自己免疫細胞療法:細胞組成物、方法およびヒト疾患の治療への応用 | |
Surls et al. | Differential effect of CD4+ Foxp3+ T-regulatory cells on the B and T helper cell responses to influenza virus vaccination | |
CN103533955A (zh) | 用于激发t细胞的方法 | |
Yu et al. | Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines | |
AU3257999A (en) | Method for activating natural killer (nk) cells | |
JP2004526455A (ja) | 単球から高度に活性なヒト樹状細胞を作製するための方法 | |
CN101085349A (zh) | 囊泡导向的免疫细胞及其在制备抗肿瘤药物上的应用 | |
KR20160104753A (ko) | 조절된 면역우세 요법 | |
Ma et al. | Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice | |
JP4852702B2 (ja) | 抗原パルスして得られた樹状細胞 | |
WO2005097976A1 (ja) | 抗原パルスして得られた樹状細胞 | |
WO2010104836A1 (en) | Infectious disease cellular immunotherapy | |
JP2015509974A (ja) | 感染治療のための活性化された免疫刺激細胞組成物 | |
US11464851B2 (en) | SARS-CoV-2 vaccines | |
EP3981425A1 (en) | Sars-cov-2 vaccines | |
JP2008536511A (ja) | CD8T細胞の活性化方法{MethodForActivatingCD8TCells} | |
FR2775692A1 (fr) | Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre | |
Leung | Effector T Lymphocytes in Defence Against Murine Influenza Virus Infection | |
CN117752781A (zh) | Mcp-1重组蛋白在制备疟疾红内期全虫灭活疫苗免疫佐剂中的应用 | |
JPWO2012160702A1 (ja) | 樹状細胞の分化・培養方法 | |
JP2008538499A (ja) | CD4T細胞の活性化方法{MethodForActivatingCD4TCells} | |
JP2003321375A (ja) | ヒトt細胞による肝疾患治療剤 | |
SE523515C2 (sv) | Ny metod och komposition för framställning av ett cellulärt allogent vaccin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512091 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580011906.2 Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase |